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Abstract. 2-Substituted derivatives of indane-1,3-dione 3a–f , 5a–g, 6a–g were synthesized and investi-
gated as anticoagulant agents. 2-Arylindane-1,3-diones (3) were obtained in the reaction of phthalide with 
appropriate arylaldehydes. 2-Arylmethyleneindane-1,3-diones (5) were prepared by condensation of 
indane-1,3-dione with the corresponding arylaldehydes. The compounds 5 were converted into their 
methyl analogues 6 by reduction with sodium tetrahydroborate. All of the compounds studied were 
screened for the anticoagulant activity. The highest prothrombin time was established for 2-[4-(methyl-
sulfanyl)phenyl]indane-1,3-dione (3c) (PT = 33.71 ( 26.01) s), which was very close to PT of the drug 
anisindione (PT = 36.0 ( 26.42) s).  
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Anticoagulants are pivotal agents for prevention and 
treatment of thromboembolic disorders.1 Recently, anti-
coagulant activities were found for sulfated polysaccha-
rides that are either of natural, semisynthetic, or synthe-
tic origin, such as dextran sulfate, chitin and chitin sul-
fate, polysaccharide sulfate, and others.2 Various anti-
coagulant-active fractions from marine algae have been 
isolated and characterized, especially from red and 
brown algae.3  
The most commonly used anticoagulants, disco-
vered in the early 1940s, are heparin, and coumarins.4 
A number of coumarin compounds possessing anticoa-
gulant activity have been synthesized as potential drugs 
for treatment of myocardial infarction.5 However, using 
both heparins and coumarins have well-known limita-
tions. They are not selective, acting on a broad range of 
substrates in the coagulation cascade.6 Drug and food 
interactions are frequently cited as causes of adverse 
events when using warfarin.7  
Warfarin [3-(α-acetonylbenzyl)-4-hydroxycoumarin] 
acts slower than heparin, though it has a number of 
advantages. Warfarin acts as an inhibitor of vitamin K 
epoxide reductase and vitamin K reductase, preventing 
generation of the reduced form of vitamin K, which is a 
necessary cofactor for the hepatic synthesis of vitamin 
K-dependent clotting factors.8, 9 The onset and duration 
of warfarin action are similar to those of 2-arylindane-
1,3-diones (anisindione, fluindione, and phenindione).10 
Like coumarins, the indane-1,3-diones are competitive 
inhibitors of vitamin K in the biosynthesis of prothrom-
bin and follow the same biochemical mechanism of 
action.11 
In our previous papers, we described the synthesis 
and the results of our preliminary pharmacological in-
vestigations of indane-1,3-diones (3), structurally re-
lated to anisindione, fluindione, or clorindione.12, 13 All 
of the explored compounds exhibit weak toxicity, and 
given at the doses equivalent to 0.1 LD50 they have no 
neurotoxic activity as they did not affect the motor 
coordination in the rota-rod and chimney tests. Due to 
the fact, that various 2-arylindane-1,3-diones, besides 
their hypolipemic, antiinflammatory and antiallergic 
activity, act mainly as anticoagulant agents, the aim of the 
present study was to investigate in vivo the anticoagulant 
activity of 3 and the novel indane-1,3-diones 5 and 6.  
614 K. Mitka et al., Novel Indane-1,3-dione Derivatives 
Croat. Chem. Acta 82 (2009) 613. 
CHEMISTRY 
Experimental 
Structures of all synthesized compounds were eluci-
dated by analytical and spectroscopic data. Melting 
points were determined on a Boëtius apparatus and 
are uncorrected. IR spectra were measured in KBr 
pellets on a Bio-Rad FTS-175C spectrophotometer. 
1D 1H NMR and 2D heteronuclear 1H-13C correlation 
spectra were taken on a Varian 300 MHz Mercury-VX 
apparatus, using CDCl3 as the solvent. The chemical 
shifts are expressed as δ values in ppm against TMS as 
an internal standard; the coupling pattern and the coup-
ling constants were taken from expanded spectra. EI 
mass spectra were recorded with a Varian – MAT 112 
spectrometer at 70 eV, and ESI+ were obtained using 
Finnigan MAT 95S instrument. Elemental analyses (C, 
H) were performed on a Perkin-Elmer 2400 analyzer 
located at the Regional Laboratory of Jagiellonian Uni-
versity, and the results are within ± 0.4 % of the calcu-
lated values. The reactions and the product purification 
were monitored by TLC on silica-gel plates (Merck 
60F254) using ethyl acetate/n-hexane (vol. ratio 1:1) 
mixture as eluent. For column chromatography, silica 
gel (Merck) was used. Starting materials, solvents, and 
reagents were purchased from commercial sources 
(Aldrich and Merck) and were used without further 
purification. 
The synthesis of the compounds 3a–f have been 
described previously.12, 13 
Synthesis of 2-Arylmethyleneindane-1,3-diones (5a–g) 
General Procedure. To a solution of indane-1,3-dione 
(4) (0.01 mol) in glacial acetic acid (10 mL) appropriate 
arylaldehydes 2a–g (0.01 mol) and catalytic amounts 
(2–3 drops) of concentrated sulfuric acid were added. 
The reaction mixture was let to stand for 72 h at room 
temperature. The solid formed was collected by filtra-
tion and recrystallized from n-octane. 
2-Benzylideneindane-1,3-dione (5a) was obtained from 
2a as brown, glitter needles, 1.38 g (58 %); m.p. 152–
153 °C; IR(KBr) νmax /cm
–1: 3066 (CH), 1728, 1685 
(CO), 1613, 1588, 1568, 1486 (C=C); 1H NMR (CDCl3) 
δ /ppm: 7.48–7.56 (m, 3H, Ar-H), 7.78–7.84 (m, 2H, 
Ar-H), 7.90 (s, 1H, CH=), 7.98–8.04 (m, 2H, Ar-H), 
8.45 (d, 2H, J = 7.6 Hz, Ar-H); MS (EI) m/z: 234 (M+, 
75 %), 233 ([M-H]+, 100 %), 206 ([M-CO]+, 7 %), 205 
([M-H-CO]+, 11 %), 177 ([M-H-2CO]+, 8 %). 
Anal. Calcd. mass fractions of elements, w/%, for  
C16H10O2 (Mr = 234.25): C 82.04, H 4.30; found: 
C 81.86, H 4.23. 
2-(4-Methoxybenzylidene)indane-1,3-dione (5b) was 
obtained from 2b as yellow needles, 1.54 g (58 %); m.p. 
156–157 °C; IR(KBr) νmax/cm
–1: 3072, 2919 (CH), 
1718, 1680 (CO), 1581, 1558, 1509 (C=C), 1268, 1250 
(O-CH3); 
1H NMR (CDCl3) δ/ppm: 3.91 (s, 3H, CH3), 
7.00 (d, 2H, J = 8.7 Hz, Ar-H), 7.78 (d, 2H, J = 8.7 Hz, 
Ar-H), 7.83 (s, 1H, CH=), 7.95–7.99 (m, 2H, Ar-H), 
8.54 (d, 2H, J = 7.1 Hz,  Ar-H); MS (ESI+) m/z: 265 
([M+H]+, 100 %). 
Anal. Calcd. mass fractions of elements, w/%, for  
C17H12O3 (Mr = 264.28): C 77.26, H 4.58; found: 
C 76.82, H 4.49. 
2-(4-Methylsulfanylbenzylidene)indane-1,3-dione (5c) 
was obtained from 2c as yellow-orange needles, 1.51 g 
(54 %); m.p. 142–143.5 °C; IR(KBr) νmax/cm
–1: 3068, 
2917 (CH), 1723, 1686 (CO), 1605, 1574, 1540 (C=C), 
1331 (S-CH3); 
1H NMR (CDCl3) δ/ppm:  2.54 (s, 3H, 
CH3), 7.30 (d, 2H, J = 6.3 Hz, Ar-H), 7.77–7.81 (m, 3H,  
Ar-H + CH=), 7.96–8.00 (m, 2H, Ar-H), 8.42 (d, 2H, J 
= 6.8 Hz,  Ar-H); MS (EI) m/z: 280 (M+, 100 %), 279 
([M-H]+, 64 %), 265 ([M-CH3]
+, 14 %), 233 ([M-
SCH3]
+, 73 %), 205 ([M-SCH3-CO]
+, 8 %), 177 ([M-
SCH3-2CO]
+, 7 %). 
Anal. Calcd. mass fractions of elements, w/%, for  
C17H12O2S (Mr = 280.34): C 72.84, H 4.31; found: 
C 72.89, H 4.23 . 
2-(1-Naphthylmethylene)indane-1,3-dione (5d) was 
obtained from 2d as orange needles, 1.83 g (64 %); m.p. 
174–176 °C; IR(KBr) νmax/cm
–1: 3090, 3057 (CH), 
1720, 1680 (CO), 1604, 1592, 1511 (C=C); 1H NMR 
(CDCl3) δ/ppm: 7.54–7.67 (m, 3H, Ar-H), 7.82–7.85 
(m, 2H, Ar-H), 7.93 (d, 1H, J = 7.5 Hz, Ar-H), 8.00–
8.08 (m, 3H, Ar-H), 8.26 (d, 1H, J = 7.4 Hz, Ar-H), 8.76 
(d, 1H, J = 7.2 Hz, Ar-H), 8.80 (s, 1H, CH=); MS (EI) 
m/z: 284 (M+, 100 %), 283 ([M-H]+, 49 %), 256 ([M-
CO]+, 14 %), 255 ([M-H-CO]+, 67 %), 227 ([M-H-
2CO]+, 19 %). 
Anal. Calcd. for C20H12O2 (Mr = 284.31): C 84.49, 
H 4.25; found: C 84.19, H 4.17. 
2-[1-(4-Methylsulfanyl)naphthylmethylene]indane-1,3-
dione (5e) was obtained from 2e as red-orange pellets, 
1.57 g (48 %); m.p. 191–191.5 °C; IR(KBr) νmax/cm
–1: 
3077, 2985 (CH), 1714, 1670 (CO), 1587, 1542, 1508 
(C=C), 1317 (S-CH3); 
1H NMR (CDCl3) δ/ppm: 2.66 (s, 
3H, CH3), 7.36 (d, 1H, J = 8.1 Hz, Ar-H), 7.54–7.68 (m, 
2H, Ar-H), 7.77–7.80 (m, 2H, Ar-H), 7.94–8.03 (m, 2H, 
Ar-H), 8.24 (d, 1H, J = 8.4 Hz, Ar-H), 8.31 (d, 1H, J = 
8.1 Hz, Ar-H), 8.74 (s, 1H, CH=), 8.94 (d, 1H, J = 8.4 
Hz, Ar-H); MS (EI) m/z: 330 (M+, 100 %), 315 ([M-
CH3]
+, 67 %), 283 ([M-SCH3]
+, 89 %), 255 ([M-SCH3-
CO]+, 48 %), 227 ([M-SCH3-2CO]
+, 45 %). 
Anal. Calcd. mass fractions of elements, w/%, for 
C21H14O2S (Mr = 330.40): C 76.34, H 4.27; found: 
C 76.44, H 4.17. 
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2-[1-(4-Ethylsulfanyl)naphthylmethylene]indane-1,3-
dione (5f ) was obtained from 2f as red-orange pellets, 
2.44 g (71 %); m.p. 145–146 °C; IR(KBr) νmax/cm
–1: 
3074, 2965 (CH), 1720, 1685 (CO), 1591, 1556, 1508 
(C=C), 1319 (S-C2H5); 
1H NMR (CDCl3) δ/ppm: 1.50 
(t, 3H, J = 7.3 Hz, CH3), 3.25 (q, 2H, J = 7.3 Hz, CH2), 
7.35 (d, 1H, J = 8.0 Hz, Ar-H), 7.55–7.70 (m, 2H, Ar-
H), 7.78–7.82 (m, 2H, Ar-H), 7.92–8.00 (m, 2H, Ar-H), 
8.26–8.33 (m, 2H, Ar-H), 8.75 (s, 1H, CH=), 8.92 (d, 
1H, J = 8.2 Hz, Ar-H); MS (EI) m/z: 344 (M+, 100 %), 
315 ([M-C2H5]
+, 65 %), 283 ([M-SC2H5]
+, 65 %), 255 
([M-SC2H5-CO]
+, 20 %), 227 ([M-SC2H5-2CO]
+, 65 %). 
Anal. Calcd. mass fractions of elements, w/%, for 
C22H16O2S (Mr = 344.43): C 76.72, H 4.68; found: 
C 76.57, H 4.29. 
2-(2-Furylmethylene)indane-1,3-dione (5g) was obtain-
ed from 2g as green-yellow needles, 1.56 g (70 %); m.p. 
209.5–211 °C; IR(KBr) νmax/cm
–1: 3140, 3102, 2922 
(CH), 1727, 1691 (CO), 1607, 1589 (C=C), 1160 (C-O-
C); 1H NMR (CDCl3) δ/ppm: 6.71–6.73 (m, 1H, Ar-H), 
7.74 (s, 1H, CH=), 7.76–7.79 (m, 3H, Ar-H), 7.95–7.98 
(m, 2H, Ar-H), 8.57 (d, 1H, J = 3.7 Hz, Ar-H); MS 
(ESI+) m/z: 225 ([M+H]+, 100 %). 
Anal. Calcd. mass fractions of elements, w/%, for 
C14H8O3 (Mr = 224.05): C 75.00, H 3.60; found: 
C 75.01, H 3.57. 
Reduction of 2-Arylmethyleneindane-1,3-diones (5a–g) 
to 2-Arylmethylindane-1,3-diones (6a–g) 
General Procedure. To a solution of 5 (3.0 mmol) in 
pyridine (15–20 mL), warmed up to 50 °C, a solution of 
NaBH4 (0.11 g, 3.0 mmol) in 5 mL of water was added 
dropwise. After the addition was complete, a few pieces 
of ice were added and the mixture was acidified to 
pH = 1 with concentrated hydrochloric acid. The organic 
product was isolated by extraction with chloroform. The 
extract was dried with anhydrous sodium sulfate and the 
solvent was evaporated. The residue was purified by 
column chromatography (silica gel-chloroform) to give 
6, which was recrystallized from an appropriate solvent. 
2-Benzylindane-1,3-dione (6a) was obtained from 5a as 
light-yellow needles (from n-octane), 0.43 g (61 %); 
m.p. 97–99 °C; IR(KBr) νmax/cm
–1: 3083, 3058, 3028, 
2929 (CH), 1742, 1708 (CO), 1601, 1590, 1492 (C=C); 
1H NMR (CDCl3) δ/ppm: 3.34 (s, 3H, CH-CH2), 7.14–
7.16 (m, 5H, Ar-H), 7.73–7.76 (m, 2H, Ar-H), 7.87–
7.90 (m, 2H, Ar-H); MS (EI) m/z: 236 (M+, 100 %), 219 
([M-OH]+, 55 %), 208 ([M-CO]+, 27 %), 191 ([M-CO-
OH]+, 10 %). 
Anal. Calcd. mass fractions of elements, w/%, for 
C16H12O2 (Mr = 236.27): C 81.34, H 5.12; found: 
C 81.10, H 5.07. 
2-(4-Methoxybenzyl)indane-1,3-dione (6b) was obtained 
from 5b as light-yellow needles (from n-octane), 0.49 g 
(62 %); m.p. 96–97.5 °C; IR(KBr) νmax/cm
–1: 3076, 
3037, 2930 (CH), 1737, 1708 (CO), 1613, 1594, 1513 
(C=C), 1253 (O-CH3); 
1H NMR (CDCl3) δ/ppm: 3.29 
(s, 3H, CH-CH2), 3.67 (s, 3H, CH3), 6.68 (d, 2H, J = 8.7 
Hz, Ar-H), 7.06 (d, 2H, J = 8.7 Hz, Ar-H), 7.73–7.76 
(m, 2H, Ar-H), 7.86–7.89 (m, 2H, Ar-H); MS (ESI+) 
m/z: 267 ([M+H]+, 100 %). 
Anal. Calcd. mass fractions of elements, w/%, for 
C17H14O3 (Mr = 266.30): C 76.68, H 5.30; found: 
C 76.97, H 5.23. 
2-(4-Methylsulfanylbenzyl)indane-1,3-dione (6c) was 
obtained from 5c as light-yellow needles (from 
n-heptane), 0.57 g (57 %); m.p. 70–71 °C; IR(KBr) 
νmax/cm
–1: 3081, 3037, 2981 (CH), 1744, 1707 (CO), 
1591, 1495 (C=C), 1325 (S-CH3); 
1H NMR (CDCl3) 
δ/ppm: 2.38 (s, 3H, CH3), 3.31 (s, 3H, CH-CH2), 7.03–
7.10 (m, 4H, Ar-H), 7.75–7.78 (m, 2H, Ar-H), 7.87–
7.90 (m, 2H, Ar-H); MS (EI) m/z: 282 (M+, 90 %), 235 
([M-SCH3]
+, 50 %), 207 ([M-SCH3-CO]
+, 18 %). 
Anal. Calcd. mass fractions of elements, w/%, for 
C17H14O2S (Mr = 282.36): C 72.32, H 5.00; found: 
C 71.94, H 4.92. 
2-(1-Naphthylmethyl)indane-1,3-dione (6d) was ob-
tained from 5d as light-yellow plates (from n-octane), 
0.53 g (62 %); m.p. 136–138 °C; IR(KBr) νmax/cm
–1: 
3076, 3048, 3018 (CH), 1747, 1703 (CO), 1594, 1510 
(C=C); 1H NMR (CDCl3) δ/ppm: 3.46 (t, 1H, J = 6.0 
Hz, CH), 3.67 (d, 2H, J = 6.0 Hz, CH2), 7.37–7.51 (m, 
3H, Ar-H), 7.55–7.60 (m, 1H, Ar-H), 7.74 (d, 1H, J = 
8.2 Hz, Ar-H), 7.79–7.86 (m, 3H, Ar-H), 7.92–7.96 (m, 
2H, Ar-H), 8.25 (d, 1H, J = 8.4 Hz, Ar-H); MS (EI) m/z: 
286 (M+, 100 %), 269 ([M-OH]+, 26 %), 268 ([M-
H2O]
+, 94 %), 258 ([M-CO]+, 13 %), 240 ([M-H2O-
CO]+, 45 %). 
Anal. Calcd. mass fractions of elements, w/%, for 
C20H14O2 (Mr = 286.33): C 83.90, H 4.93; found: 
C 83.60, H 4.84. 
2-[1-(4-Methylsulfanyl)naphthylmethyl]indane-1,3-
dione (6e) was obtained from 5e as yellow plates (from 
n-octane), 0.77 g (76 %); m.p. 125–126 °C; IR(KBr) 
νmax/cm
–1: 3087, 3056, 2930 (CH), 1742, 1704 (CO), 
1589, 1566, 1510 (C=C), 1326 (S-CH3); 
1H NMR 
(CDCl3) δ/ppm: 2.54 (s, 3H, CH3), 3.42 (t, 1H, J = 5.9 
Hz, CH), 3.62 (d, 1H, J = 5.9 Hz, CH2), 7.29 (d, 1H, J = 
7.5 Hz, Ar-H), 7.40 (d, 1H, J = 7.6 Hz, Ar-H), 7.51–
7.63 (m, 2H, Ar-H), 7.78–7.81 (m, 2H, Ar-H), 7.91–
7.94 (m, 2H, Ar-H), 8.24–8.31 (m, 2H, Ar-H); MS (EI) 
m/z: 332 (M+, 44 %), 317 ([M-CH3]
+, 1 %), 285 ([M-
SCH3]
+, 4 %), 257 ([M-SCH3-CO]
+, 2 %) 229 ([M-
SCH3-2CO]
+, 2 %). 
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Anal. Calcd. mass fractions of elements, w/%, for 
C21H16O2S (Mr = 332.42): C 75.88, H 4.85; found: 
C 75.62, H 4.74. 
2-[1-(4-Ethylsulfanyl)naphthylmethyl]indane-1,3-dione 
(6f ) was obtained from 5f as orange needles (from 
n-octane), 0.20 g (26 %); m.p. 69–70 °C; IR(KBr) 
νmax/cm
–1: 3060, 2974 (CH), 1741, 1703 (CO), 1589, 
1565, 1510 (C=C), 1324 (S-C2H5); 
1H NMR (CDCl3) 
δ/ppm: 1.29 (t, 3H, J = 7.1 Hz, CH3), 2.98 (q, 2H, J = 
7.1 Hz, CH2), 3.40 (t, 1H, J = 5.9 Hz, CH), 3.61 (d, 1H, 
J = 5.9 Hz, CH2), 7.27 (d, 1H, J = 7.4 Hz, Ar-H), 7.40 
(d, 1H, J = 7.5 Hz, Ar-H), 7.50–7.63 (m, 2H, Ar-H), 
7.78–7.82 (m, 2H, Ar-H), 7.91–7.94 (m, 2H, Ar-H), 
8.23–8.29 (m, 2H, Ar-H); MS (EI) m/z: 346 (M+, 50 %), 
317 ([M-C2H5]
+, 3 %), 285 ([M-SC2H5]
+, 4 %), 257 
([M-SC2H5-CO]
+, 1 %), 229 ([M-SC2H5-2CO]
+, 3 %). 
Anal. Calcd. mass fractions of elements, w/%, for 
C22H18O2S (Mr = 346.44): C 76.27, H 5.24; found: 
C 76.55, H 5.39.   
2-(2-Furylmethyl)indane-1,3-dione (6g) was obtained 
from 5g as yellow plates (from n-heptane), 0.48 g 
(70 %); m.p. 97.5–98 °C; IR(KBr) νmax/cm
–1: 3081, 
2919 (CH), 1747, 1704 (CO), 1591, 1507 (C=C), 1164 
(C-O-C); 1H NMR (CDCl3) δ/ppm: 3.31 (t, 1H, J = 5.7 
Hz, CH),  3.38 (d, 2H, J = 5.5 Hz, CH2), 5.98–6.00 (m, 
1H, Ar-H), 6.12–6.13 (m, 1H, Ar-H), 7.08–7.09 (m, 1H, 
Ar-H), 7.78–7.84 (m, 2H, Ar-H), 7.92–7.98 (m, 2H, Ar-
H); MS (ESI+) m/z: 227 ([M+H]+, 100 %). 
Anal. Calcd. mass fractions of elements, w/%, for 
C14H10O3 (Mr = 226.23): C 74.33, H 4.46; found: 
C 74.21, H 4.54. 
Results and discussion 
2-Arylindane-1,3-diones (3a–f ) have been prepared by 
condensing phthalide (1) with appropriate arylaldehydes 
(2a–f), in the presence of sodium methoxide in ethyl 
acetate (Scheme 1). By this method 2-arylindane-1,3-
diones (3a, c–f ) as well as the anisindione (3b) ap-
proved as an anticoagulant drug, were obtained.12, 13 
In order to check the influence of modification of 
2-arylindane-1,3-diones (3a–f ) on their anticoagulant 
properties 2-arylmethylene- (5a–g) and 2-arylmethyl-
indane-1,3-diones (6a–g), possessing the additional 
methine and methylene units respectively, were also 
obtained (Scheme 2). The compounds 5a–g were pre-
pared by condensation of indane-1,3-dione (4) with the 
corresponding arylaldehydes 2a–g. The reactions were 
carried out in glacial acetic acid in the presence of con-
centrated sulfuric acid as a catalyst at room temperature. 
The 2-arylmethyleneindane-1,3-diones (5a–g) were 
prepared in acceptable yields (Scheme 2).14 All of the  
2-arylmethyleneindane-1,3-diones were colored crystal-
line solids with sharp melting points. 
The compounds 5a–g were converted into their sa-
turated analogues 6a–g by reduction of 5a–g with so- 
dium tetrahydroborate in pyridine at 50 °C (Scheme 2).15 
It is worth pointing out that under the reduction condi-
tions applied, only the reduction of C=C bonds in 5a–g 
took place, without any effect on the C=O bonds. It is a 
well known fact that NaBH4 has a great tendency 
to effect double reduction of conjugated C=C–C=O 
systems.  Moreover, even in the case of single reduction 
the product of C=O bond reduction is usually formed in 
a larger amount.  In our investigations, we did not iso-
late any products of C=O bond reduction in any case.  
The structure of the compounds 5a–g and 6a–g 
was identified by analytical and spectroscopic data. 
In all the 1H NMR spectra of 5a–g, protons of –CH= 
were within the aromatic region. Unexpectedly, in the 
1H NMR spectra of 6a–c, protons of CH–CH2 units 
were observed as singlets at δ 3.29–3.34 ppm. This 
phenomenon may be attributed to structural symmetry 
of 6a–c. Inspection of the heteronuclear 1H-13C correla-
tion spectra of 6a–c, showed cross-peaks between pro-
tons at two different C-atoms. For example, Figure 1 
shows 1H-13C COSY spectrum of 6b – the proton signal 
at δ 3.29 ppm, gives a cross-peak with the composite 
signal of carbons in CH2 (δ 31.42 ppm) and CH (δ 55.26 
ppm). In the 1H NMR spectra of structurally unsymme-
trical derivatives 6d–g protons in CH–CH2 units appear 
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All of the synthesized compounds 3, 5 and 6 were screened 
for their anticoagulant activity, and the data obtained were 
compared with anticoagulant effect of warfarin. Warfarin 
potasium was purchased from LG Promochem. All agents 
were suspended in 100 % olive oil.  
Drugs Administration 
The compounds tested and warfarin were administered 
orally to male mice (Balb/c) at doses 10 and 50 mg/kg 
for compounds 3, 5 and 6 and 1 mg/kg for warfarin, for 
four consecutive days (at 9:00 am). On the day 5, 18–20 
hours after the last drug administration, blood samples 
were collected by aspiration from the inferior vena 
cava of mice, previously anaesthetized with ketha-
mine/xilazine mixture (vol. ratio 87:13). As an anticoa-
gulant, 3 % w  sodium citrate was used. Platelets-poor 
plasma was separated by centrifugation at 5000 g for 7 
minutes at room temperature. 
PT Assay 
Anticoagulant activity in plasma samples was measured 
by microplate-based blood coagulation assay16 using 
kinetic microplate reader (FluoroStar Optima, BMG). 
To measure prothrombin time (PT) 100 µL of plasma 
was incubated for 1 min at 37 C and the coagulation 
was induced by addition of 200 µL of PT reagent 
(HemoStat THROMBOPLASTIN-SI, HUMAN). Clot-
ting time was determined by change in absorbance at 
405 nm. The method was previously validated using 
normal and abnormal human plasmas (HUMAN). 
Statistical Analysis 
All PT data represent mean values  SD. Statistical 
analysis was performed by ANOVA test. A P value of 
less then 0.05 was considered as significant. 
Results and discussion 
All of the orally given compounds at 10 mg/kg doses 
did not prolong prothrombin time after 4 days of conti-
Figure 1. 1H-13C COSY spectrum of 2-{[(4-methoxy)phenyl]-
methyl}indane-1,3-dione (6b). 
 
Figure 2. Anticoagulation effect of the compounds 3, 5 and 6 and warfarin in mice. The drugs and warfarin were given orally for
4 consecutive days at the doses 10 mg/kg, 50 mg/kg and 1 mg/kg, respectively. The data represent the prothrombin time in plas-
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nuous feeding, except for 3d and to a very little extent 
5f, for which the measured PT was (17.88  6.14) s and 
(12.39  1.39) s, respectively. The controls were: place-
bo – (10.46  0.62) s and warfarin (1 mg/kg) – (25.22  
9.13) s. For 3d and 5f  P < 0.05, for warfarin P < 0.01, 
both compared with placebo group. The compounds 
studied were also tested at the doses 50 mg/kg given 
orally for 4 consecutive days. Only 3b, 3c, 3d, 5f, and 
3e affected the coagulation, significantly prolonging the 
clotting time. The results of PT were 36.0 ( 26.42); 
33.71 ( 26.01); 26.39 ( 15.75); 22.93 ( 5.25); 13.97 
( 1.87) s respectively. P values for active compounds 
were < 0.05, compared with placebo group. All the 
remaining compounds induced very small anticoagula-
tion effect (Figure 2). 
Amongst the obtained compounds screened for 
their anticoagulant activity, the highest prothrombin 
time was found for 2-(4-methylsulfanylphenyl)indane-
1,3-dione (3c) (PT = 33.71 ( 26.01) s), which is very 
close to the PT of the drug anisindione (3b) (PT = 36.0 
( 26.42) s). Hence, the replacement of the methoxy 
substituent in the structure of 2-(4-methoxyphenyl)-
indane-1,3-dione (3b) with a methylsulfanyl group, 
practically does not affect the protrombin times of the 
compounds studied. Both these compounds, however, 
are ca. five times less active than warfarin. Moreover, 
the data obtained indicate that generally the presence 
of additional methine (compounds 5) and methylene 
(compounds 6) units in the structure of 2-arylindane-
1,3-dione induces a very small anti-coagulation effect.
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Sinteza novih derivata indan-1,3-diona i biološko ispitivanje 
njihovog antikoagulacijskog djelovanja  
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aInstitute of Organic Chemistry and Technology, Cracow University of Technology, 
24 Warszawska St., 31-155 Kraków, Poland  
bPharmaceutical Company Adamed Ltd, Pieńków 149, 05-152 Czosnów, Poland  
Pripravljeni su 2-supstituirani derivati indan-1,3-diona 3a–f, 5a–g, 6a-g i ispitivano njihovo antikoagulacijsko dje-
lovanje. 2-Arilindan-1,3-dioni (3) dobiveni su reakcijom ftalida s odgovarajućim aldehidima. 2-Arilmetilenindan-
1,3-dioni (5) pripravljeni su kondenzacijom indan-1,3-diona s odgovarajućim aldehidima. Redukcijom s natrije-
vim tetrahidroboranom spojevi 5 prevedeni su u metil-analoge 6. Svim spojevima ispitivana je antikoagulacijska 
aktivnost. Najduže protrombinsko vrijeme nađeno je za 2-[4-(metilsulfanil)fenil]indan-1,3-dion (3c) 
(PT = 33,71 ( 26,01) s), što je vrlo slično PT-u lijeka anisindiona (PT = 36,0 ( 26,42) s) 
